Anti-CD2 monoclonal antibodies synergize with anti-CD3 to prolong allograft survival and decrease cytokine production.
Chavin
K D
KD
Department of Surgery, Medical University of South Carolina, Charleston 29425.
Qin
L
L
Lin
J
J
Kaplan
A J
AJ
Bromberg
J S
JS
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology* / Q000502:physiology; D000954:Antigens, Surface / Q000276:immunology; D018801:CD2 Antigens; D017252:CD3 Complex / Q000276:immunology*; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D004357:Drug Synergism; D005434:Flow Cytometry; D006085:Graft Survival / Q000276:immunology*; D016027:Heart Transplantation / Q000276:immunology*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D008808:Mice, Inbred CBA; D011971:Receptors, Immunologic / Q000276:immunology* / Q000502:physiology; D014184:Transplantation, Homologous
D000911:Antibodies, Monoclonal; D000945:Antigens, Differentiation, T-Lymphocyte; D000954:Antigens, Surface; D018801:CD2 Antigens; D017252:CD3 Complex; D016207:Cytokines; D007166:Immunosuppressive Agents; D011971:Receptors, Immunologic